Novartis Foundation and partners launch new hypertension program in Ghana
(Thomson Reuters ONE) -
Novartis International AG /
Novartis Foundation and partners launch new hypertension program in Ghana
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Community-based Hypertension Improvement Project (ComHIP) is an innovative
healthcare model designed to improve hypertension management and control
* Screening and treatment is shifted to the community and technology supports
healthcare workers and empowers patient self-management
* More than one quarter of the adult population in Ghana has hypertension, but
only 4% of these hypertensive patients have it under control
* Program partners include FHI 360, Ghana Health Service, London School of
Hygiene & Tropical Medicine, VOTO Mobile and many local partners
The digital press release with multimedia content can be accessed here:
Basel, October 29, 2015 - The Novartis Foundation and its partners have begun
screening patients in the Community-based Hypertension Improvement Project
(ComHIP), a two-year program designed to evaluate the impact of an innovative
healthcare model on hypertension management and control in Ghana.
With the innovative healthcare model, the Novartis Foundation and its partners
aim to improve the control of hypertension, a major risk factor for
cardiovascular disease, by making services more accessible in the community
while empowering individuals to manage their hypertension. More than three
quarters of deaths from cardiovascular disease take place in low- and middle-
income countries.[1]
"We've taken lessons from previous work in infectious disease to create ComHIP,
a unique healthcare model that joins together public-private partnerships,
community-based healthcare services and technology that supports healthcare
workers and drives patient education," said Peter Lamptey, President Emeritus,
FHI 360 and Professor of Non-communicable Diseases, London School of Hygiene &
Tropical Medicine. "We want to empower the whole community from patients to
healthcare workers to local businesses to reduce the burden of hypertension, and
- hopefully - to improve the healthcare system overall."
Carried out in a district close to an urban center in Ghana, ComHIP will shift
the point where patients access healthcare from the hospital, which is often
distant and crowded, to the community. Local businesses and healthcare workers
based in the community will be trained to screen and care for hypertensive
patients. Mobile devices and telemedicine will be used to support community
nurses in decision making and ensuring seamless connection with community
healthcare workers and physicians as needed. In addition, SMS / voice messaging
will be used for patient education to reduce risk factors for cardiovascular
disease and to support adherence to therapy.
"We are really excited to see ComHIP gain momentum and I am confident the
results of the program will help inform policy that improves hypertension care
in Ghana at a national level," said Ann Aerts, Head of the Novartis Foundation.
"In addition, the Novartis Foundation's goal extends beyond Ghana and
hypertension. We seek to build evidence on what type of healthcare delivery
models and technologies are effective, and then adapt and apply them to help
manage the overall dual burden of infectious and non-communicable diseases that
low- and middle-income countries are facing."
Low- and middle-income countries (LMICs) are still coping with infectious
diseases and maternal and child health issues, while at the same time, the
burden of non-communicable diseases (NCDs) such as heart disease, diabetes and
cancer has risen dramatically. Almost 70% of all deaths globally are associated
with NCDs and four out of five of these deaths occur in LMICs.[2]
Deaths from hypertension are estimated at 9.4 million people annually globally,
which is equivalent to all infectious diseases combined.[3] More than a quarter
of the adult population in Ghana has hypertension[4], but only 4% of these
patients have their blood pressure under control.[5]
The Novartis Foundation is collaborating on ComHIP with FHI 360, the Ghana
Health Service, the London School of Hygiene & Tropical Medicine Centre for
Global NCDs, VOTO Mobile, the School of Public Health at the University of Ghana
and many local partners in Ghana.
About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative
healthcare models that can have a transformational impact on the health of the
poorest populations. We work hand-in-hand with our local and global partners to
catalyze scalable and sustainable healthcare models to improve access and health
outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing
on interventions that aim to interrupt transmission. Everything we do is
grounded in evidence and innovation, and our work is a continuous cycle of
evaluation, adaptation and application. In 2014, the operational budget for the
foundation was CHF 12 million and our programs reached 3.6 million people.
For more information, please visit:
www.novartisfoundation.org
www.youtube.com/novartisfoundation
Novartis Foundation is on Twitter. Sign up to follow (at)NovartisFDN at
https://twitter.com/NovartisFDN
Disclaimer
This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as "launch,"
"aim," "want," "hopefully," "will," "excited," "confident," "goal," "seek,"
"pioneering," "efforts," or similar expressions. Such forward-looking statements
reflect the current views of the Group regarding future events, and involve
known and unknown risks, uncertainties and other factors that may cause actual
results to be materially different from any future results expressed or implied
by such statements. These expectations could be affected by, among other things,
risks and factors referred to in the Risk Factors section of Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update it in the future.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
References
[1.] World Health Organization. Cardiovascular diseases (CVDs) fact sheet. 2015
http://www.who.int/mediacentre/factsheets/fs317/en/#
[2.] World Health Organization. Global status report on non-communicable
diseases, 2014.
[3.] Angell, Sonia Y.; Decock, Kevin M.; Frieden, Thomas R. A public health
approach to global management of hypertension. The Lancet,
2015, 385.9970: 825-827. Lim, Stephen S., et al. A comparative risk assessment
of burden of disease and injury attributable to 67 risk factors and risk factor
clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden
of Disease Study 2010. The lancet, 2013, 380.9859: 2224-2260.
[4.] World Health Organization, Non-communicable Diseases (NCD) Country
Profiles: Ghana. Available at: http://www.who.int/nmh/countries/gha_en.pdf?ua=1.
Last accessed May 2015.
[5.] Lloyd-Sherlock, Peter, et al. Hypertension among older adults in low-and
middle-income countries: prevalence, awareness and control. International
journal of epidemiology, 2014, 43.1: 116-128.
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Julie Morrow
Novartis Global Media Relations Novartis Foundation
+41 61 324 7999 (direct) +41 61 696 2421 (direct)
+41 79 593 4202 (mobile) +41 79 224 5666 (mobile)
eric.althoff(at)novartis.com julie.morrow(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1962153/715576.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1962153]
Unternehmensinformation / Kurzprofil:
Datum: 29.10.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 430308
Anzahl Zeichen: 11152
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis Foundation and partners launch new hypertension program in Ghana"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
